ReviewBreast cancer research : BCR2020

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.

Claudio Vernieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.